ReferenceCitation: Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387.

ReferenceCitation: Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 Apr;124(8):1388-1397. doi: 10.1038/s41416-021-01260-w. Epub 2021 Feb 3.

family: Zhu

full_name: Andrew X. Zhu

given: Andrew X.

family: Finn

full_name: Richard S. Finn

given: Richard S.

family: Kang

full_name: Yoon-Koo Kang

given: Yoon-Koo

family: Yen

full_name: Chia-Jui Yen

given: Chia-Jui

family: Galle

full_name: Peter R. Galle

given: Peter R.

family: Llovet

full_name: Josep M. Llovet

given: Josep M.

family: Assenat

full_name: Eric Assenat

given: Eric

family: Brandi

full_name: Giovanni Brandi

given: Giovanni

family: Motomura

full_name: Kenta Motomura

given: Kenta

family: Ohno

full_name: Izumi Ohno

given: Izumi

family: Daniele

full_name: Bruno Daniele

given: Bruno

family: Vogel

full_name: Arndt Vogel

given: Arndt

family: Yamashita

full_name: Tatsuya Yamashita

given: Tatsuya

family: Hsu

full_name: Chih-Hung Hsu

given: Chih-Hung

family: Gerken

full_name: Guido Gerken

given: Guido

family: Bilbruck

full_name: John Bilbruck

given: John

full_name: Yanzhi Hsu

given: Yanzhi

family: Liang

full_name: Kun Liang

given: Kun

family: Widau

full_name: Ryan C. Widau

given: Ryan C.

family: Wang

full_name: Chunxiao Wang

given: Chunxiao

family: Abada

full_name: Paolo Abada

given: Paolo

family: Kudo

full_name: Masatoshi Kudo

given: Masatoshi

journal_name: British Journal of Cancer

ReferenceCitation: Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 Mar;41(3):598-607. doi: 10.1111/liv.14731. Epub 2020 Dec 5.

name: Barcelona Clinic Liver Cancer Group, Liver Unit Hospital Clínic of Barcelona. IDIBAPS. CIBERehd. University of Barcelona Barcelona Spain

name: Department of Internal Medicine Mainz University Medical Center Mainz Germany

name: Departments of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

name: Division of Hematology/Oncology University of California Los Angeles CA USA

name: Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY USA

name: Translational Research in Hepatic Oncology, Liver Unit IDIBAPS, Hospital Clinic Barcelona, University of Barcelona Barcelona Spain

name: Institució Catalana d’Estudis Avançats (ICREA) Barcelona Spain

name: Eli Lilly and Company Indianapolis IN USA

name: Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA

name: Jiahui International Cancer Center Jiahui Health Shanghai China

repository_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

ReferenceCitation: Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 2020 Aug;5(4). pii: e000797. doi: 10.1136/esmoopen-2020-000797.

ReferenceCitation: Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 2020 Jun;55(6):627-639. doi: 10.1007/s00535-020-01668-w. Epub 2020 Feb 27.

ReferenceCitation: Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Erratum in: Eur J Cancer. 2018 Sep;100:135-136.

ReferenceCitation: Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol. 2017 Feb 1;3(2):235-243. doi: 10.1001/jamaoncol.2016.4115.

name: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston

name: California Pacific Medical Center, San Francisco

name: Otto von Guericke University of Magdeburg, Magdeburg, Germany

name: Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan

name: Saga-Ken Medical Centre Koseikan, Saga, Japan

name: Surgery Department CHU Estaing, Clermond Ferrand, France

name: Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany

name: Policlinico Sant' Orsola-Malpighi, Bologna, Italy

name: Catholic University of Sacred Heart, Rome, Italy

name: Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

name: National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

name: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

name: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

name: Gangnam Severance Hospital, Seoul, South Korea

name: Yonsei Cancer Center, Cancer Metastasis Research Center, Yonsei University College of Medicine, Shinchon-Dong, South Korea

name: Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan17National Yang-Ming University School of Medicine, Taipei, Taiwan

name: National Cheng Kung University Hospital, Tainan City, Taiwan

name: Chang Gung Memorial Hospital, Chiayi, Taiwan

name: Eli Lilly and Company, Bridgewater, New Jersey

name: AstraZeneca Pharmaceuticals, Wilmington, Delaware

name: Eli Lilly and Company, Indianapolis, Indiana

name: Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom

ReferenceCitation: Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017 Apr;52(4):494-503. doi: 10.1007/s00535-016-1247-4. Epub 2016 Aug 22.

ReferenceCitation: Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

location_country:
Finland
Romania
Australia
Belgium
Czech Republic
Taiwan
France
Japan
Thailand
Norway
Canada
Korea, Republic of
Sweden
Hong Kong
Netherlands
Philippines
Switzerland
Bulgaria
Hungary
Portugal
Germany
United States
Italy
Austria
Brazil
Israel
Spain

title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

summary:
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.

Approximately 544 participants, at least 18 years of age, with Child-Pugh score < 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.

Hypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.

Upon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.

The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision.


design_allocation: Randomized

intervention_type: Drug

status: Completed

study_type: Interventional

lead_sponsor: Sanofi

enrollment_type: Actual

primary_purpose: Treatment

location_country:
Austria
Brazil
Sweden
Mexico
Netherlands
Finland
France
Greece
Israel
Slovakia
Ireland
Russian Federation
Spain
Turkey
United States
Czech Republic
Canada

acronym: EAGLE

location_facility:
Investigational Site Number 124-008
Investigational Site Number 376003
Investigational Site Number 840016
Investigational Site Number 076-005
Investigational Site Number 376004
Investigational Site Number 703001
Investigational Site Number 840031
Investigational Site Number 040-001
Investigational Site Number 724001
Investigational Site Number 840038
Investigational Site Number 724010
Investigational Site Number 076-002
Investigational Site Number 840011
Investigational Site Number 752-001
Investigational Site Number 250-017
Investigational Site Number 250-004
Investigational Site Number 124-004
Investigational Site Number 840008
Investigational Site Number 840033
Investigational Site Number 840047
Investigational Site Number 300004
Investigational Site Number 040-007
Investigational Site Number 643006
Investigational Site Number 752-006
Investigational Site Number 792-002
Investigational Site Number 124-003
Investigational Site Number 840028
Investigational Site Number 840043
Investigational Site Number 724007
Investigational Site Number 840007
Investigational Site Number 250-021
Investigational Site Number 528006
Investigational Site Number 703004
Investigational Site Number 840049
Investigational Site Number 840045
Investigational Site Number 840042
Investigational Site Number 250-016
Investigational Site Number 250-006
Investigational Site Number 840005
Investigational Site Number 840014
Investigational Site Number 528005
Investigational Site Number 840009
Investigational Site Number 724009
Investigational Site Number 484003
Investigational Site Number 792-001
Investigational Site Number 840020
Investigational Site Number 643007
Investigational Site Number 840023
Investigational Site Number 300001
Investigational Site Number 076-001
Investigational Site Number 250-007
Investigational Site Number 040-003
Investigational Site Number 752-002
Investigational Site Number 752-005
Investigational Site Number 840001
Investigational Site Number 250-011
Investigational Site Number 203001
Investigational Site Number 840036
Investigational Site Number 840052
Investigational Site Number 840010
Investigational Site Number 724003
Investigational Site Number 703003
Investigational Site Number 840034
Investigational Site Number 724005
Investigational Site Number 752-007
Investigational Site Number 721002
Investigational Site Number 840013
Investigational Site Number 840019
Investigational Site Number 840048
Investigational Site Number 246004
Investigational Site Number 484001
Investigational Site Number 724008
Investigational Site Number 840035
Investigational Site Number 703002
Investigational Site Number 840046
Investigational Site Number 643-009
Investigational Site Number 076-007
Investigational Site Number 840037
Investigational Site Number 203005
Investigational Site Number 840050
Investigational Site Number 643001
Investigational Site Number 840015
Investigational Site Number 250-009
Investigational Site Number 124-006
Investigational Site Number 528004
Investigational Site Number 840051
Investigational Site Number 203006
Investigational Site Number 724006
Investigational Site Number 076-006
Investigational Site Number 040-006
Investigational Site Number 840039
Investigational Site Number 840002
Investigational Site Number 040-004
Investigational Site Number 703005
Investigational Site Number 300003
Investigational Site Number 643004
Investigational Site Number 250022
Investigational Site Number 246002
Investigational Site Number 840024
Investigational Site Number 203003
Investigational Site Number 840022
Investigational Site Number 203002
Investigational Site Number 246003
Investigational Site Number 076-004
Investigational Site Number 250-008
Investigational Site Number 528007
Investigational Site Number 840027
Investigational Site Number 250-020
Investigational Site Number 372001
Investigational Site Number 040-002
Investigational Site Number 840004
Investigational Site Number 840030
Investigational Site Number 840026
Investigational Site Number 250-002
Investigational Site Number 484002
Investigational Site Number 246001
Investigational Site Number 752-03
Investigational Site Number 040-005
Investigational Site Number 643008
Investigational Site Number 376002
Investigational Site Number 840017
Investigational Site Number 484004
Investigational Site Number 840029
Investigational Site Number 528003
Investigational Site Number 840006
Investigational Site Number 124-001
Investigational Site Number 528002
Investigational Site Number 724004
Investigational Site Number 250-003
Investigational Site Number 643005
Investigational Site Number 643003
Investigational Site Number 840044
Investigational Site Number 840012
Investigational Site Number 124-007
Investigational Site Number 528001
Investigational Site Number 250-012

study_completion_date_type: Actual

type: EudraCT Number

type: Other Identifier

source: euctr

title: A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide

summary:
Primary objective:

To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents

Secondary objectives of the comparative period (24 weeks):

>To assess the effect of insulin glargine in comparison with liraglutide on:

HbA1c level
Percentage of patients whose HbA1c has decreased but remains >= 7% at the end of the comparative period
Percentage of patients whose HbA1c has increased at the end of the comparative period
Fasting Plasma Glucose (FPG)
7-point Plasma Glucose (PG) profiles
Hypoglycemia occurrence
Body weight
Adverse events

Objectives of the extension period (24 weeks):

>To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on:

HbA1c level
FPG
7-point PG profiles
Hypoglycemia occurrence
Body weight
Adverse events

lead_sponsor_type: industriel

status_simplified: Completed


title: A Phase III Trial Comparing High Versus Standard Dose of Prophylactic Cranial Irradiation (PCI) in Limited Small Cell Lung Cancer Complete Responders

summary:
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and prevent the spread of cancer to the brain. It is not yet known if standard-dose radiation therapy is more effective than high-dose radiation therapy in preventing the spread of limited-stage small cell lung cancer cells to the brain.

PURPOSE: This randomized phase III trial is comparing two different regimens of radiation therapy to see how well they work in treating patients with limited-stage small cell lung cancer in complete remission.

ReferenceType: background

ReferenceCitation: Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. doi: 10.1016/S1470-2045(09)70101-9. Epub 2009 Apr 20.

ReferenceCitation: Pechoux CL, Hatton M, Kobierska A, et al.: Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): primary endpoint analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA7514, 2008.

ReferenceType: result

ReferenceCitation: Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, Keus R, Hatton M, Videtic GM, Senan S, Wolfson A, Jones R, Arriagada R, Quoix E, Dunant A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol. 2011 May;22(5):1154-1163. doi: 10.1093/annonc/mdq576. Epub 2010 Dec 7.

family: Le Péchoux

full_name: C. Le Péchoux

given: C.

sequence: first

family: Laplanche

full_name: A. Laplanche

given: A.

sequence: additional

family: Faivre-Finn

full_name: C. Faivre-Finn

family: Ciuleanu

full_name: T. Ciuleanu

given: T.

family: Wanders

full_name: R. Wanders

given: R.

family: Lerouge

full_name: D. Lerouge

given: D.

family: Keus

full_name: R. Keus

family: Hatton

full_name: M. Hatton

given: M.

family: Videtic

full_name: G.M. Videtic

family: Senan

full_name: S. Senan

given: S.

family: Wolfson

full_name: A. Wolfson

family: Jones

full_name: R. Jones

family: Arriagada

full_name: R. Arriagada

family: Quoix

full_name: E. Quoix

given: E.

family: Dunant

full_name: A. Dunant

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Annals of Oncology

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: open (via crossref license)

host_type: publisher

license: elsevier-specific: oa user license

license_normalized: elsevier-specific

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

license_normalized: no license

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via pmcid lookup)

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

lead_sponsor: Gustave Roussy, Cancer Campus, Grand Paris

location_country: Macedonia, The Former Yugoslav Republic of

location_facility: Cancer Therapy Centre at Campbelltown Hospital

location_facility: Hopital d'Instruction des Armes Sainte-Anne

location_facility: Cancer Research Centre at Weston Park Hospital

location_facility: Centre Hospitalier Sud Francilien - Site Corbeil

location_facility: University Medical Center Rotterdam at Erasmus Medical Center

location_facility: Northern Centre for Cancer Treatment at Newcastle General Hospital

location_facility: Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

location_facility: Centre de Lutte Contre le Cancer Georges-Francois Leclerc

location_facility: Akademisch Ziekenhuis Vrije Universiteit - Medisch Centrum

location_facility: Centre Hospitalier Universitaire Vaudois

location_facility: M.D. Anderson Cancer Center at University of Texas

location_facility: Institute of Oncology at Vilnius University

location_facility: Institute of Oncology and Radiology of Serbia

location_facility: Nijmegen Cancer Center at Radboud University Medical Center

location_facility: Institutul Oncologic - Universitatea de Medicina

location_facility: Velindre Cancer Center at Velinde Hospital

location_facility: Cazk Groeninghe - Campus Maria's Voorzienigheid

location_facility: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

location_facility: Centre Hospitalier Universitaire Henri Mondor

location_facility: Mount Vernon Cancer Centre at Mount Vernon Hospital

location_facility: Ospedale Ostetrico Ginecologica Sant Anna

location_facility: Centre Hospital Regional Universitaire de Limoges

location_facility: First Medical Clinic of Charles University Hospital

intervention_type: Radiation

lead_sponsor_type: academique


title: Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma

summary:
RATIONALE: Surgery may be an effective treatment for neuroblastoma.

PURPOSE: This phase II trial is studying how well surgery works in treating patients with neuroblastoma.

status: Unknown status

enrollment_type: Anticipated

lead_sponsor: Societe Internationale d'Oncologie Pediatrique

location_country:
Italy
Austria
Switzerland
Netherlands
France
Ireland
Spain
United Kingdom

location_facility: Azienda Ospedaliera - Universitaria di Modena

location_facility: Centre Hospitalier Universitaire de Dijon

location_facility: Fondazione I.R.C.C.S. Policlinico San Matteo

location_facility: Centre Hospitalier Regional et Universitaire de Lille

location_facility: Fondazione Istituto Nazionale dei Tumori

location_facility: Northern Centre for Cancer Treatment at Newcastle General Hospital

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: Hospital Universitario Central de Asturias

location_facility: Royal Belfast Hospital for Sick Children

location_facility: Allgemeines Krankenhaus - Universitatskliniken

location_facility: Great Ormond Street Hospital for Children

location_facility: Academisch Medisch Centrum at University of Amsterdam

location_facility: Royal Liverpool Children's Hospital, Alder Hey

location_facility: Our Lady's Hospital for Sick Children Crumlin

intervention_type: Procedure

status_simplified: Unknown


type: Registry Identifier

title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

acronym: EXAMINE

summary: The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

ReferenceType: derived

ReferenceCitation: Ferreira JP, Mehta C, Sharma A, Nissen SE, Rossignol P, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Med. 2020 Jun 4;18(1):165. doi: 10.1186/s12916-020-01616-8.

family: Ferreira

full_name: João Pedro Ferreira

given: João Pedro

family: Mehta

full_name: Cyrus Mehta

given: Cyrus

family: Sharma

full_name: Abhinav Sharma

given: Abhinav

family: Nissen

full_name: Steven E. Nissen

given: Steven E.

family: Rossignol

full_name: Patrick Rossignol

given: Patrick

family: Zannad

full_name: Faiez Zannad

given: Faiez

currency_apc_doaj: GBP

journal_name: BMC Medicine

oa_colors: green gold

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

repository_normalized: HAL

version: submittedVersion

repositories:
HAL
PubMed Central

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 Jan 7;9(1):e012797. doi: 10.1161/JAHA.119.012797. Epub 2020 Jan 4.

name: INSERM CIC 1433 NI‐CRCT (Cardiovascular and Renal Clinical Trialists) F‐CRIN network Université de Lorraine and CHRU Nancy France

name: Division of Cardiology Stanford University Palo Alto CA

name: Division of Cardiology McGill University Montreal QC Canada

name: Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston MA

family: Vaduganathan

full_name: Muthiah Vaduganathan

given: Muthiah

name: Department of Physiology University of Porto Portugal

name: Baim Institute for Clinical Research Boston MA

family: Liu

full_name: Yuyin Liu

given: Yuyin

name: University of Chicago Medicine Chicago IL

family: Bakris

full_name: George L. Bakris

name: University of Connecticut School of Medicine Farmington CT

journal_name: Journal of the American Heart Association

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

publisher: Ovid Technologies (Wolters Kluwer Health)

ReferenceCitation: White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

name: Memphis Veterans Affairs Medical Center University of Tennessee Health Science Center Memphis TN

name: Baim Clinical Research Institute Boston MA

name: Harvard School of Public Health Boston MA

title: Average Clinician‐Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial

ReferenceCitation: Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. Diabetes Care. 2018 Jul;41(7):1510-1515. doi: 10.2337/dc18-0109. Epub 2018 May 30.

ReferenceCitation: Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 May 16;7(11). pii: e007649. doi: 10.1161/JAHA.117.007649.

name: INSERM CIC 1433 Université de Lorraine and CHRU, Nancy, France

name: Duke Clinical Research Institute, Duke University, Durham, NC

name: Division of Cardiology, Stanford University, Palo Alto, CA

name: Baim Institute for Clinical Research, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

name: University of Connecticut School of Medicine, Farmington, CT

name: University of Chicago Pritzker School of Medicine, Chicago, IL

name: Memphis Veterans Affairs Medical Center, University of Tennessee College of Medicine, Memphis, TN

title: Early and Chronic Dipeptidyl‐Peptidase‐IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial

ReferenceCitation: White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med. 2018 Jul;131(7):813-819.e5. doi: 10.1016/j.amjmed.2018.02.023. Epub 2018 Mar 23.

ReferenceCitation: Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 Mar;20(3):654-659. doi: 10.1111/dom.13136. Epub 2017 Nov 21.

name: Division of Endocrinology and Metabolism, Department of Medicine; Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong; Seoul South Korea

name: Cardiovascular Division; Brigham and Women's Hospital; Boston Massachusetts

name: Baim Institute for Clinical Research; Boston Massachusetts

name: International Diabetes Center, Park-Nicollet Clinic; Minneapolis Minnesota

name: Harvard School of Public Health; Boston Massachusetts

name: University of Tennessee College of Medicine; Memphis Tennessee

name: University of Chicago Med; Chicago Illinois

name: University of Connecticut School of Medicine; Farmington Connecticut

repository_institution: Harvard University - Digital Access to Scholarship at Harvard (DASH)

ReferenceCitation: Kay S, Strickson A, Puelles J, Selby R, Benson E, Tolley K. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Ther. 2017 Apr;8(2):251-273. doi: 10.1007/s13300-017-0245-8. Epub 2017 Mar 8. Review.

ReferenceCitation: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16;135(20):1911-1921. doi: 10.1161/CIRCULATIONAHA.116.024632. Epub 2017 Feb 28.

name: From University of North Carolina, Chapel Hill (M.A.C.); Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Department of Pathology (P.J.) and TIMI Study Group (D.A.M.), Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; University of Chicago, IL (G.L.B.); Memphis Veterans Affairs Medical Center, University of Tennessee College of Medicine (W.C.C.); Takeda Development Center Americas, Inc., Deerfield, IL (S.K.); Baim Institute for Clinical...

ReferenceCitation: White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP; EXAMINE Investigators. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul;39(7):1267-73. doi: 10.2337/dc16-0303. Epub 2016 Jun 11.

ReferenceCitation: Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10.

ReferenceCitation: White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.

repository_institution: The University of Queensland - Queensland's institutional digital repository

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: Aston University - Aston Publications Explorer

title: Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

ReferenceCitation: White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct;162(4):620-626.e1. doi: 10.1016/j.ahj.2011.08.004. Epub 2011 Sep 14.

title: EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

location_country:
Peru
Guatemala
Finland
Malaysia
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Czech Republic
Taiwan
Ukraine
India
Spain
Croatia
France
Japan
Lithuania
Kuwait
Poland
Slovakia
Argentina
Thailand
Canada
Korea, Republic of
Colombia
South Africa
Chile
Sweden
United Arab Emirates
Hong Kong
Philippines
Bulgaria
Hungary
Puerto Rico
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Serbia
Mexico
Israel
Egypt
New Zealand
Turkey
Latvia


ReferenceCitation: Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14.

ReferenceCitation: Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

study_start_date_type: Actual

lead_sponsor: Celgene

location_country:
Italy
United States
Sweden
France
Spain
Germany
United Kingdom
Canada

location_facility: Ematologia ed Immunologia, Azienda Ospedaliera "Vito Fazzi" di Lecce

location_facility: Wake Forest University School of Medicine

location_facility: Northwestern University Medical Center Division of Hematology Oncology

location_facility: Azienda Ospedaliera Universitaria San Martino

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: University of Ulm Abteilung Innere Medizin III

location_facility: Drexel University, College of Medicine, Clinical Research Group

location_facility: Desert Hematology Oncology Medical Group, Inc.

location_facility: Long Island Jewish Medical Center CLL Research and Treatment Program

title: A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

summary: The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).


design_allocation: Non-Randomized

status: Recruiting

lead_sponsor: Bristol-Myers Squibb

location_country:
Peru
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Norway
Argentina
Canada
Korea, Republic of
Chile
Sweden
Switzerland
Netherlands
Hungary
Ireland
China
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Czechia
Israel
Spain

acronym: Pan tumor Nivolumab Rollover Study

location_facility: N.N. Blokhin National Medical Research Center of Oncology

location_facility: Cliniques Universitaires UCL de Mont-Godinne (CHU)

location_facility: Hospital Universitario y Politecnico de La Fe

location_facility: The University of Chicago Medical Center

location_facility: Centro de Investigacion Clinica Montesur

location_facility: Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari

location_facility: Pole Biologie Pathologie Genetique - CHU de Lille

location_facility: Universitaetsspital Basel - Klinik fuer Onkologie

location_facility: Hospital Regional Universitario Carlos Haya

location_facility: CAIPO Centro para la Atencion Integraldel Paciente Oncologico

location_facility: East &amp, North Hertfordshire NHS Trust

location_facility: Sotiria General Hospital of Chest Diseases

location_facility: Centre Hospitalier Intercommunal de Creteil CHIC

location_facility: Osaka Medical and Pharmaceutical University Hospital

location_facility: GU Research Network/Urology Cancer Center

location_facility: Irmandade da Santa Casa de Misericordia de Porto Alegre

location_facility: Catalan Institute of Badalona Hospital Germans Trias i Pujol ICO

location_facility: Istituto Nazionale Tumori - Fondazione Pascale Italy

location_facility: Centro Hospitalar de Lisboa Norte EPE - HPV

location_facility: Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre

location_facility: Centro Oncologico y de Investigacion Buenos Aires

location_facility: Orszagos Koranyi TBC es Pulmonologiai Intezet

location_facility: Instituto Portugues de Oncologio de Lisboa

location_facility: Bradford Hill Centro de Investigacion Clinica

location_facility: Hillman Cancer Center- U of Pitts Cancer Institute

location_facility: North Coast Area Health Service NCAHS - The North Coast Cancer Institute NCCI - Coffs Harbour Health

location_facility: UW Health - UW Carbone Cancer Center - Medical Oncology Clinic

location_facility: Hospital General Universitario de Alicante

location_facility: Centro Oncologico MD ANDERSON Internacional Espana

location_facility: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

location_facility: Universitaetsklinikum Jena - Klinik und Poliklinik fuer Urologie

location_facility: Hospital Universitario Fundacion Jimenez Diaz

location_facility: UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center

location_facility: Ms Pneumed Janusz Milanowski Katarzyna Szmygin-Milanowska Sp. J.

location_facility: Fundacio Investigao Hospital General Universitario de Valencia FiHgU

location_facility: Istituto Nazionale dei Tumori Regina Elena

location_facility: Fondazione IRCCS Istituto Nazionale Tumori

location_facility: Kobe City Medical Center General Hospital

location_facility: Niigata University Medical and Dental Hospital

location_facility: UniversitaetsSpital Zuerich - Dermatology

location_facility: Georgetown-Lombardi Comprehensive Cancer Center

location_facility: H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

location_facility: Azienda ospedaliero-universitaria Senese di Santa Maria alle Scotte

location_facility: Institutul Oncologic Prof. Dr. I. Chiricuta

study_completion_date_type: Anticipated

title: Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab

summary: Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.

status_simplified: Ongoing


lead_sponsor: Merck Sharp & Dohme Corp.

location_country:
Greece
Romania
Australia
Russian Federation
Ukraine
France
Poland
Norway
Argentina
Canada
Colombia
Chile
Hungary
Ireland
Portugal
United States
Germany
United Kingdom
Italy
Brazil
Mexico
Israel
Spain

acronym: Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC

location_facility: GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 1171)

location_facility: Universitaetsklinikum Tuebingen ( Site 0409)

location_facility: Spitalul de Psihiatrie Titan Dr. Constantin Gorgos ( Site 1112)

location_facility: Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1258)

location_facility: Uniwersyteckie Centrum Kliniczne-Klinka Chirurgii Onkologicznej ( Site 0960)

location_facility: Boca Raton Regional Hospital ( Site 1551)

location_facility: City of Hope Medical Center ( Site 1505)

location_facility: Massachusetts General Hospital ( Site 1518)

location_facility: Universitatsklinikum Giessen und Marburg GmbH ( Site 0413)

location_facility: Institut Claudius Regaud IUCT Oncopole ( Site 0354)

location_facility: Oncologos del Occidente S.A. ( Site 0206)

location_facility: Azienda Ospedaliero Universitaria Pisana ( Site 0603)

location_facility: Winship Cancer Institute of Emory University ( Site 1512)

location_facility: Hifu Terramed Conformal SRL ( Site 1111)

location_facility: University of Kentucky School of Medicine & Hospitals ( Site 1542)

location_facility: CH Lyon Sud Hospices Civils de Lyon ( Site 0350)

location_facility: Oncological Dispensary #2 of Ministry of Health of Krasnodar region ( Site 1159)

location_facility: University of California Davis Comprehensive Cancer Center ( Site 1560)

location_facility: S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101)

location_facility: Royal Marsden NHS Foundation Trust ( Site 1408)

location_facility: University of Colorado Cancer Center ( Site 1506)

location_facility: European Interbalkan Medical Center ( Site 0455)

location_facility: Universitaetsklinikum Berlin - Charite - Campus Mitte ( Site 0400)

location_facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0601)

location_facility: University College Hospital London ( Site 1400)

location_facility: Zaitsev V.T. Institute of General and Urgent Surgery of the -Department of Purulent Surgery ( Site 1

location_facility: Smilow Cancer Center at Yale-New Haven ( Site 1507)

location_facility: Szabolcs Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz ( Site 0500)

location_facility: Hospital Universitario Ramon y Cajal ( Site 1251)

location_facility: First Moscow State Medical University n.a. I.M.Sechenov ( Site 1164)

location_facility: Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (

location_facility: John Theurer Cancer Center at Hackensack University Medical Center ( Site 1526)

location_facility: Haddassah Medical Organization - Ein Kerem ( Site 0553)

location_facility: Centro de Investigación Clínica de Alta Especialidad ( Site 0715)

location_facility: Guy s & St Thomas NHS Foundation Trust ( Site 1407)

location_facility: Stanford University Medical Center ( Site 1503)

location_facility: Istituto Europeo di Oncologia ( Site 0602)

location_facility: Hospital de Caridade de Ijui ( Site 0100)

location_facility: The Royal Marsden Hospital-Institute of Cancer Research ( Site 1406)

location_facility: Centro de Investigación Oncológica del Norte ( Site 1652)

location_facility: University of Iowa Hospital and Clinics ( Site 1514)

location_facility: CHRU de Lille - Hopital Claude Huriez ( Site 0355)

location_facility: The Ottawa Hospital Cancer Centre ( Site 0154)

location_facility: Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1152)

location_facility: Centre Hospitalier Annecy Genevois ( Site 0361)

location_facility: Instituto Portugues de Oncologia de Lisboa ( Site 1003)

location_facility: S C Oncocenter Oncologie Medicala S R L ( Site 1106)

location_facility: Instituto Nacional de Cancerologia E.S.E ( Site 0204)

location_facility: Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0201)

location_facility: Gold Coast University Hospital ( Site 0054)

location_facility: Hospital General Universitari Vall d Hebron ( Site 1252)

location_facility: The University of Texas-MD Anderson Cancer Center ( Site 1536)

location_facility: Universitaetsklinikum Essen ( Site 0403)

location_facility: Hospital Universitario Carlos Haya ( Site 1255)

location_facility: Hospital Clinic i Provincial Barcelona ( Site 1253)

location_facility: Sumy regional clinical oncological dispensary-Oncothoracic department ( Site 1452)

location_facility: Szent Imre Egyetemi Oktatokorhaz ( Site 0502)

location_facility: Hospital Particular do Algarve ( Site 1005)

location_facility: Inova Schar Cancer Institute ( Site 1538)

location_facility: Udmurtia Republic Regional Clinical Oncology Dispensary ( Site 1158)

location_facility: C.H.U. de Nimes. Hopital Caremeau ( Site 0368)

location_facility: West Cancer Center - East Campus ( Site 1535)

location_facility: Centro Estatal de Cancerologia de Chihuahua ( Site 0703)

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0600)

location_facility: Papageorgiou General Hospital ( Site 0451)

location_facility: Onco-Hematologia de Occidente ( Site 0716)

location_facility: Consultorios de Medicina Especializada del Sector Privado ( Site 0701)

location_facility: Centro Oncologico Riojano Integral ( Site 0002)

location_facility: Hospital Italiano- Sociedad Italiana de Beneficencia en Buenos Aires ( Site 0009)

location_facility: Oslo Universitetssykehus Radiumhospitalet ( Site 0850)

location_facility: Vanderbilt Ingram Cancer Center ( Site 1543)

location_facility: Centro Oncológico de Rosario ( Site 0003)

location_facility: Hospital Sao Vicente de Paulo ( Site 0105)

location_facility: Nizhniy Novgorod regional clinical oncological dispensary ( Site 1169)

location_facility: Soroka University Medical Center ( Site 0555)

location_facility: Attikon University General Hospital of Athens ( Site 0454)

location_facility: CHU de Bordeaux- Hopital Saint Andre ( Site 0370)

location_facility: Hospital de Especialidades Centro Medico de Occidente ( Site 0704)

location_facility: Altay Regional Oncology Dispensary ( Site 1168)

location_facility: Indiana University Melvin and Bren Simon Cancer Center ( Site 1515)

location_facility: MUSC Hollings Cancer Center ( Site 1533)

location_facility: CHU Besancon - Hopital Jean Minjoz ( Site 0359)

location_facility: Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0951)

location_facility: Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1000)

location_facility: Hospital Universitario Marques de Valdecilla ( Site 1256)

location_facility: Centro de atencion e investigacion clinica en oncologia ( Site 0706)

location_facility: Providence Portland Medical Center ( Site 1530)

location_facility: Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 1451)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 0959)

location_facility: Medizinische Hochschule Hannover ( Site 0405)

location_facility: Royal Cornwall Hospitals NHS Trust ( Site 1402)

location_facility: University of South Alabama, Mitchell Cancer Institute ( Site 1562)

location_facility: Spitalul Universitar CF Cluj-Napoca ( Site 1103)

ipd_sharing: Yes

title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

summary: This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).


ipd_sharing_description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.

lead_sponsor: Astellas Pharma Global Development, Inc.

location_country:
Italy
France
Japan
Ireland
Australia
Spain
United States
Korea, Republic of
Taiwan

location_facility: MultiCare Regional Cancer Center - Gig Harbor

location_facility: Mary Bird Perkins - Our Lady of the Lake Cancer Center

location_facility: Cancer Treatment Centers of America at Eastern Regional Medical Center

location_facility: Cancer Treatment Centers of America, Chicago

title: A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

summary:
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).


title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

acronym: AXIOMATIC-SSP

summary: The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.

primary_purpose: Prevention

location_country:
Finland
Greece
Australia
Belgium
Russian Federation
Denmark
France
Japan
Poland
Norway
Argentina
Canada
Korea, Republic of
Chile
Sweden
Hong Kong
Switzerland
Hungary
China
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Czechia
Israel
Spain

location_facility: University of Texas Health Science Center at Houston

location_facility: Hospital of The University of Pennsylvania

location_facility: Mercyhealth Javon Bea Hospital- Riverside

location_facility: University of Illinois Hospital & Health Sciences System

location_facility: University of North Carolina at Chapel Hill

location_facility: UCLA Ronald Reagan University of California Los Angeles Medical Center

location_facility: University Hospitals Cleveland Medical Center

location_facility: Kaiser Permanente Los Angeles Medical Center

location_facility: The Ohio State University Wexner Medical Center

location_facility: Dell Seton Medical School at The University of Texas - Stroke Institute

location_facility: University of Alabama at Birmingham: The Kirklin Clinic

intervention_type: Other


title: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

summary: The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

ReferenceCitation: Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.

name: Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA

family: Bekaii-Saab

full_name: Tanios S Bekaii-Saab

given: Tanios S

name: Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, The University of Manchester, Manchester, UK

family: Valle

full_name: Juan W Valle

given: Juan W

name: Department of Oncology, University of Leuven, Leuven, Belgium

family: Cutsem

full_name: Eric Van Cutsem

given: Eric Van

name: Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy

name: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

family: Rimassa

full_name: Lorenza Rimassa

given: Lorenza

name: Department of Medical Oncology, Kyorin University, Tokyo, Japan

family: Furuse

full_name: Junji Furuse

given: Junji

name: Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan

family: Ioka

full_name: Tatsuya Ioka

given: Tatsuya

name: Department of Medicine, University of Verona, Verona, Italy

family: Melisi

full_name: Davide Melisi

given: Davide

name: Medical Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Barcelona, Spain

family: Macarulla

full_name: Teresa Macarulla

given: Teresa

name: Research Department of Oncology, UCL Cancer Institute, University College London, London, UK

family: Bridgewater

full_name: John Bridgewater

given: John

name: Department of Medical Oncology, Hammersmith Hospital, Imperial College Health Care Trust, London, UK

family: Wasan

full_name: Harpreet Wasan

given: Harpreet

family: Borad

full_name: Mitesh J Borad

given: Mitesh J

name: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

name: Department of Medicine, Weill Medical College, Cornell University, New York, NY, USA

family: Abou-Alfa

full_name: Ghassan K Abou-Alfa

given: Ghassan K

family: Jiang

full_name: Ping Jiang

given: Ping

family: Lihou

full_name: Christine F Lihou

given: Christine F

family: Zhen

full_name: Huiling Zhen

given: Huiling

name: Incyte Biosciences International Sàrl, Morges, Switzerland

family: Asatiani

full_name: Ekaterine Asatiani

given: Ekaterine

family: Féliz

full_name: Luis Féliz

given: Luis

name: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

family: Vogel

full_name: Arndt Vogel

given: Arndt

journal_name: Future Oncology

oa_colors: green other

evidence: open (via page says license)

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

repository_institution: KU Leuven - Lirias

repository_normalized: LIRIAS (KU Leuven)

version: acceptedVersion

repository_institution: University College London - UCL Discovery

repositories_institution: University College London - UCL Discovery

ipd_sharing_description:
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

location_country:
Italy
Austria
United States
Sweden
Switzerland
Netherlands
Spain
Germany
Finland
France
Japan
Israel
Norway
Ireland
Belgium
China
Denmark
Canada
United Kingdom

location_facility: Hospital General Universitario Vall D Hebron

location_facility: Centre Hospitalier Universitaire de Besancon

location_facility: Universitaire Ziekenhuis Leuven - Gasthuisberg

location_facility: National Hospital Organization Kyushu Cancer Center

location_facility: Centro Ricerche Cliniche Di Verona (Crc)

location_facility: Tongji Hospital Huazhong University of Science and Technology

location_facility: Virginia Mason Med Ctr/Dept of Hematology/Oncology

location_facility: Universita Degli Studi Della Campania Luigi Vanvitelli U.O.C. Oncologia Medica

location_facility: Hospital Regional Universitario de Malaga

location_facility: Rabin Medical Center - Beilinson Hospital

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: University Hospital Coventry and Warwickshire

location_facility: Johns Hopkins Medicine - the Sidney Kimmel Comprehensive Cancer Center

location_facility: Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano

location_facility: Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

location_facility: Istituto Nazionale Tumori Irccs Fondazione Pascale

location_facility: Chu Ucl Namur University Hospital Mont-Godinne

location_facility: Centre Hospitalier Universitaire de Poitiers

location_facility: Irccs Azienda Ospedaliera Universitaria San Martino

location_facility: University Medical Centre Hamburg-Eppendorf Centre of Oncology

location_facility: Chu Vandoeuvre-Les-Nancy Hopital Brabois

location_facility: University College London Hospitals (Uclh)

location_facility: Istituto Nazionale Tumori Regina Elena Irccs

location_facility: Winship Cancer Institute of Emory University

location_facility: HOPITAL CHARLES NICOLLE CHU ROUEN - Hï¿½PITAL DE BOIS-GUILLAUME

location_facility: Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

location_facility: The Royal Marsden Nhs Foundation Trust - Sutton

location_facility: Fondazione Irccs Istituto Nazionale Dei Tumori

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA ï¿½ MALPIGHI

location_facility: Kent Oncology Centre - Maidstone Hospital

location_facility: Texas Oncology-Baylor Charles A. Sammons

location_facility: Hopital Europeen Georges Pompidou (Hegp)

location_facility: Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte

location_facility: Klinikum Der Johann Wolfgang Goethe University

location_facility: Greenville Health System Cancer Institute

location_facility: Hospital General Universitario de Valencia

location_facility: Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz

location_facility: Imperial College Healthcare Nhs Trust - Hammersmith Hospital

location_facility: The Royal Marsden Nhs Foundation Trust - Chelsea

location_facility: Azienda Ospedaliera San Camillo Forlanini

location_facility: Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari

location_facility: Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo

location_facility: Azienda Ospedaliera Universitaria Pisana

location_facility: Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau

location_facility: University Clinic Carl Gustav Carus Technical University Dresden

location_facility: Medizinische Universitat Wien Allgemeines Krankenhaus Der Stadt Wien

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti

location_facility: Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque

location_facility: Charite Universitaetsmedizin Berlin - Campus Charite Mitte

location_facility: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

location_facility: Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele

location_facility: University of Rochester, James P. Wilmot Cancer Center

location_facility: Hadassah Hebrew University Medical Center Ein Karem Hadassah


title: SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

acronym: SELECT

summary: The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

status: Active, not recruiting

ReferenceCitation: Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020 Nov;229:61-69. doi: 10.1016/j.ahj.2020.07.008. Epub 2020 Jul 17.

family: Ryan

full_name: Donna H. Ryan

given: Donna H.

family: Lingvay

full_name: Ildiko Lingvay

given: Ildiko

family: Colhoun

full_name: Helen M. Colhoun

given: Helen M.

family: Deanfield

full_name: John Deanfield

family: Emerson

full_name: Scott S. Emerson

given: Scott S.

family: Kahn

full_name: Steven E. Kahn

given: Steven E.

family: Kushner

full_name: Robert F. Kushner

given: Robert F.

family: Marso

full_name: Steve Marso

given: Steve

family: Plutzky

full_name: Jorge Plutzky

given: Jorge

family: Brown-Frandsen

full_name: Kirstine Brown-Frandsen

given: Kirstine

family: Gronning

full_name: Marianne O.L. Gronning

given: Marianne O.L.

family: Hovingh

full_name: G. Kees Hovingh

given: G. Kees

family: Holst

full_name: Anders Gaarsdal Holst

given: Anders Gaarsdal

family: Ravn

full_name: Henrik Ravn

given: Henrik

family: Lincoff

full_name: A. Michael Lincoff

given: A. Michael

journal_name: American Heart Journal

license: cc-by-nc

license_normalized: cc-by-nc

repository_institution: University of Edinburgh - Edinburgh Research Explorer

repository_normalized: UCL Discovery

ReferenceCitation: Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10:CD013650. doi: 10.1002/14651858.CD013650.pub2. Review.

name: Department of Cardiology; St. Luke's International Hospital; Tokyo Japan

name: Penn Medicine Nudge Unit; University of Pennsylvania Philadelphia; Philadelphia PA USA

name: Leonard Davis Institute for Health Economics; University of Pennsylvania; Philadelphia PA USA

name: Division of Cardiovascular Medicine; Hospital of the University of Pennsylvania; Philadelphia PA USA

name: Division of Biostatistics and Bioinformatics, Graduate School of Public Health; St. Luke’s International University; Tokyo Japan

name: Department of Gerontological Nursing and Healthcare Systems Management, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan

name: Department of Gerontological Nursing; Kyorin University; Tokyo Japan

name: Alice Lee Center for Nursing Studies; NUS Yong Loo Lin School of Medicine; Singapore Singapore

name: Department of Human Nutrition; University of Warmia and Mazury; Olsztyn Poland

name: Department of Cardiology and Cardiosurgery; School of Medicine, University of Warmia and Mazury; Olsztyn Poland

name: Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing; University of Glasgow; Glasgow UK

name: Barts Heart Centre; St Bartholomew's Hospital, Barts Health NHS Trust; London UK

name: Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan

ipd_sharing_description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

location_country:
Finland
Malaysia
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
India
Croatia
France
Japan
Poland
Thailand
Norway
Argentina
Canada
Colombia
South Africa
Sweden
Netherlands
Bulgaria
Hungary
Ireland
Algeria
Puerto Rico
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Serbia
Mexico
Czechia
Israel
Spain
Turkey
Latvia


title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

summary: The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

ipd_sharing_description:
Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.

This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

lead_sponsor: Eli Lilly and Company

location_country:
Malaysia
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
India
Croatia
France
Lithuania
Japan
Poland
Slovakia
Argentina
Canada
Korea, Republic of
Saudi Arabia
Switzerland
Netherlands
Hungary
Ireland
China
Germany
United States
United Kingdom
Italy
Austria
Serbia
Mexico
Czechia
Israel
Spain
Turkey
Latvia

location_facility: Centre Hospitalier de Wallonie picarde - CHwapi A.S.B.L.

location_facility: Ruijin Hospital Shanghai Jiaotong University School of Medicine

location_facility: Hospices Civils de Lyon - Centre Hospitalier Lyon Sud -

location_facility: Ishida Clinic of IBD and Gastroenterology

location_facility: The Affiliated 2nd Hosp. of Third Military Med. Univ. of PLA

location_facility: UMC Utrecht, Dept. of Internal Medicine, MDL

location_facility: Clinical Trials Center of Medical Institute

location_facility: Communal Enterprise "Odesa Regional Clinical Hospital"

location_facility: Complexo Hospitalario Universitario A Coruña, CHUAC

location_facility: Tokushukai Sapporo Higashi Tokushukai Hospital

location_facility: University of Oklahoma Health Sciences Center

location_facility: DRC Gyogyszervizsgalo Rendelointezet Kft

location_facility: Instituto de Investigaciones Clinicas Quilmes

location_facility: CHI Prof.O.O.Shalimov Kharkiv City Clinical Hospital #2

location_facility: Gastroenterology Research of San Antonio

location_facility: Hamburgisches Forschungsinstitut fuer Chronisch Entzuendliche Darmerkrankungen

location_facility: Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

location_facility: Escorts Heart Institute and Research Centre Ltd

location_facility: KM Management spol. s r.o. Gastroenterologicke a hepatologicke centrum

location_facility: Institute of Digestive and Liver Diseases

location_facility: Communal City Clinical Hospital of Ambulance

location_facility: Renji Hospital Affliated to Shanghai Jiaotong University

location_facility: Communal Non-Commercial Enterprise of Lviv Regional Council Lviv Regional Clinical Hospital

location_facility: Fakultna nemocnica s poliklinikou Roosevelta Banska Bystrica

location_facility: University of Texas Medical Branch at Galveston

location_facility: Communal Institution of Kyiv Regional Council Kyiv Regional Hospital #2

location_facility: Treatment-Diagnostic Center of Private Enterprise of PPC Atsynus

location_facility: Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital

location_facility: Inflammatory Bowel Disease Centre Montreal General Hospital - MUHC

location_facility: The First Affiliated Hospital of Anhui Medical University

location_facility: Hopital de Hautepierre - Service d'Hépatogastroentérolgie

location_facility: Ivano-Frankivsk Regional Clinical Hospital

location_facility: Delta Waves Sleep Disorders and Research Center

location_facility: Gastro I s.r.o., Gastroenterologická ambulancia

location_facility: Kunming Medical College Affiliated First Hospital

location_facility: Xiangya Hospital Central South University

location_facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology

location_facility: Clinical Research Institute of Michigan, LLC

location_facility: Bangalore Medical College and Research Institute

location_facility: Riga Eastern Clinical University Hospital

location_facility: Atlanta Gastroenterology Specialists, PC

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: Charité Universitätsmedizin Berlin Campus Buch

location_facility: State Autonomous Institution of Healthcare "Republican Clinical Hospital of the Ministry of Healthcare of Republic Tatarstan"

location_facility: Care Access Research LLC - Salt Lake City

location_facility: Vilnius University Hospital Santariskiu Clinics

location_facility: Moscow Budgetary State Healthcare Institution City Clinical Hospital 24

location_facility: Research Associates of South Florida, LLC

location_facility: Center for Advanced Gastroenterology, PLLC

location_facility: Azienda Ospedaliera Universitaria Careggi

location_facility: Centro Para el Desarrollo de la Medicina y de Asistencia Med

location_facility: Szpital Uniwersytecki Nr 2 w Bydgoszczy, Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej

location_facility: Multidisciplinary Medical Clinic "Anthurium"

location_facility: The Sixth Affiliated Hospital, Sun Yat-Sen University

location_facility: NYU Langone Long Island Clinical Research Associates

location_facility: Karelia Republican Hospital V.A. Baranova

location_facility: Nanjing Medical University - Nanjing Jiangning Hospital

location_facility: King Faisal Specialist Hospital & Research Center

location_facility: The Center for Gastrointestinal Disorders

location_facility: Medical and Sanitary Division of Severstal

location_facility: Azienda Ospedaliera Universitaria Policlinico Tor Vergata

location_facility: Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona Medicina Interna

location_facility: Showa University Northern Yokohama Hospital

location_facility: Lviv Clinical Hospital at Railway Transport of Division Healthcare Center PJSC Ukrainian Railway Sta

location_facility: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

location_facility: Pusat Penyelidikan Klinikal (CRC), Hospital Raja Perempuan Zainab II

location_facility: Centro de Investigaciones Metabólicas (CINME)

location_facility: Jiangsu Province Hospital of Chinese Medicine

location_facility: SBHI Regional Clinical Hospital #2 MoH of Krasnodar region

location_facility: The Affiliated Drum Tower Hospital of Nanjing University

location_facility: Wake Forest University School of Medicine

location_facility: CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM

location_facility: Twoja Przychodnia-Szczecinskie Centrum Medyczne

location_facility: Galilee Medical Center Department of Internal Medicine A

location_facility: The Gordon and Leslie Diamond Health Care Centre

location_facility: Wojewodzki Specjalistyczny Szpital w Olsztynie

location_facility: Apollo Research and Innovations, Apollo Hospitals International Ltd

location_facility: West Central Gastroenterology d/b/a Gastro Florida

location_facility: The Catholic University of Korea, St. Vincent's Hospital

location_facility: Soroka Medical Center - Pediatric Outpatient Clinic

location_facility: Vinnytsia RCH of Veterans of War Dept of Therapy#1 Vinnytsia M.I.Pyrogov NMU

location_facility: Azienda Ospedaliera Universitaria Policlinico de Modena

location_facility: University of Massachusetts Medical Center

location_facility: Hospital Universitario Marques De Valdecilla

location_facility: Praxis Balsiger, Seibold & Partner und Crohn-Colitis-Zentrum

location_facility: Centre de santé et de services sociaux Champlain-Charles-Le Moyne

location_facility: Gastroenterology and Endoscopy Unit IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation

location_facility: Saint Petersburg State Medical University n.a. Pavlov I.P.

location_facility: The First Hospital Affiliated to AMU (Southwest Hospital)

location_facility: The Second Affiliated Hospital of Zhejiang University School of Med

location_facility: No.1 Hospital Affiliated to Xinjiang Medical University

location_facility: Univerzitna nemocnica Bratislava-Nemocnica Stare Mesteo

location_facility: University of Arizona, CATS Research Center

location_facility: Clinical Research of West Florida, Inc. (Clearwater)

location_facility: Yaroslavl Municipal HI Clinical Hospital #8

location_facility: First Affiliated Hosp of College of Med, Zhejiang University

location_facility: Studiengesellschaft BSF Unternehmergesellschaft haftungsbeschraenkt

location_facility: Centro de Investigación Clínica Acelerada

location_facility: Gastromed Kopoń Zmudziński I Wspólnicy Spółka Jawna Specjalistyczne Centrum Gastrologii I Endoskopii

location_facility: Pusat Perubatan University Kebangsaan Malaysia

location_facility: Hospital Universitario Reina Sofia Comite Etico

location_facility: Communal Institution "Poltava Reg.Cl.H. n.a.M.V.Sklifosovskogo"

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 4

location_facility: Clinical Applications Laboratories, Inc.

location_facility: Sankikai Yokohama Shin midori General Hospital

location_facility: Tokyo Medical And Dental University Medical Hospital

location_facility: Centrum Zdrowia Matki, Dziecka i Młodzieży (CZMDM) Przychodnie

location_facility: Clinical Center Kragujevac Gastroenterohepatology Clinic

location_facility: The Catholic University of Daejeon St. Mary's Hospital

location_facility: The Second Affiliated Hospital of Wenzhou Medical College

location_facility: The Second Hospital of Dalian Medical University

location_facility: Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.

location_facility: Doctors Hospital at Renaissance Research Institute

location_facility: Private Small Enterprise, Medical Center Pulse

location_facility: CHU de Poitiers- Service d'Hépato-gastro-entérologie,

location_facility: The University of Hong Kong-Shenzhen Hospital

location_facility: Hospital of Lithuanian University of Health Sciences Kaunas

location_facility: Gastroenterology Associates of Western Michigan, P.L.C.

location_facility: CHU Amiens Picardie-Site Sud - RDC Service Hépato gastro

location_facility: SBI of Healthcare of Leningrad region "Clinical Interregional Hospital of Tosno"

location_facility: Hospital Privado Centro Medico de Cordoba SA

location_facility: Poona Medical Foundation. Ruby Hall Clinic

location_facility: Datta Meghe Institute of Medical Sciences (DU), Acharya Vinoba Bhave Rural Hospital

location_facility: Communal institution of the Kyiv Regional Council "Kyiv Regional Clinical Oncology Dispensary"

location_facility: Centre for Liver Research & Diagnostics, Deccan College of Medical Sciences, Owaisi Hospital & Research Centre

location_facility: Mautalen Salud e Investigacion-Centro de Osteopatías Médicas

location_facility: Irkutsk State Medical Academy of Continuing Education

location_facility: Private Healthcare Institution Clinical Hospital Russian Railways - Medicine of Nizhniy Novgorod

location_facility: Pauls Stradins Kliniska Universitates Slimnica

location_facility: The First People's Hospital of Yunnan Province

location_facility: Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont I. Belgyogyaszati Klinika

location_facility: Digestive Health Specialists of the Southeast

location_facility: Hospital Universitario Central de Asturias

location_facility: Gastroenterology Associates of Pensacola, PA

location_facility: Indywidualna Specjalistyczna Praktyka Lekarska

location_facility: LLC Scientific Research Centre EKO-Bezopasnost

location_facility: Kocaeli University Medical Faculty Hospital

location_facility: Saint-Petersburg City Hospital of Saint Elizabeth

location_facility: Allen Whey Khye Lim Professional Corporation

location_facility: Azienda Ospedaliero Universitaria San Martino

location_facility: Shinseikai Sai Gastroenterology, proctology

location_facility: Kyungpook National University Medical Center Chilgok Hospital

location_facility: Melbourne Gastrointestinal Investigation Unit (MGIU)

location_facility: Toho University School of Medicine, Sakura Hospital

location_facility: NZOZ ALL-MEDICUS, Zaklad Gastroenterologii

location_facility: Non-state Healthcare Institution "Roadway Clinical Hospital of OJSC Russian Railways"

location_facility: Nizhegorodskiy Regional Clinical Hospital N.A.Semashko

location_facility: Cotton-O'Neil Clinical Research Center, Digestive Health

location_facility: Medical Center of Limited Liability Company Medical Center Clinic of Family Medicine

location_facility: Niepubliczny Zaklad Opieki Zdrowotnej SONOMED

location_facility: A. Novak Transcarpathian Regional Clinical Hospital

location_facility: Acibadem Universitesi - Acibadem Kozyatagi Hastanesi

location_facility: Endomed, s.r.o.- Gastroenterologicka ambulancia

location_facility: Center Hospital of the National Center for Global Health and Medicine

location_facility: Azienda ospedaliero-universitaria Mater Domini

location_facility: Hacettepe University Faculty of Medicine

location_facility: Azienda Ospedaliero-Universitaria Santa Maria della Misericordia Gastroenterologia

location_facility: Kitasato University Kitasato Institute Hospital


location_country:
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
Spain
Croatia
France
Lithuania
Poland
Slovakia
Norway
Argentina
Moldova, Republic of
Canada
Slovenia
Korea, Republic of
South Africa
Sweden
Saudi Arabia
Switzerland
Netherlands
Bulgaria
Hungary
Ireland
China
Portugal
Germany
United States
United Kingdom
Italy
Austria
Bosnia and Herzegovina
Serbia
Mexico
Czechia
Israel
Georgia
Belarus
Turkey
Latvia

location_facility: Institute of Gastroenterology and Hepatology at Ha'Emek Medical Center

location_facility: Atlanta Center For Gastroenterology, P.C.

location_facility: Polish Mother's Memorial Hospital - Research Institute

location_facility: Assistance Publique - Hopitaux de Paris - Hopital Beaujon

location_facility: City Clinical Hospital No 31 - St. Petersburg

location_facility: Mid America Gastrointestinal Consultants

location_facility: Dr. Carol Davila Central Military Emergency Clinical Hospital

location_facility: Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

location_facility: City Clinical Hospital n.a. V.M. Buyanov

location_facility: Krajská nemocnice Pardubice, Kožní oddelení

location_facility: JSC Evex Medical Corporation - Oncology Center

location_facility: University of Oklahoma Health Sciences Center

location_facility: Harvard Medical School - Boston Children's Hospital

location_facility: Azienda Socio Sanitaria Territoriale (ASST) di Monza

location_facility: Joint Venture Company Diagnostic Center, Bioterm Ltd.

location_facility: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

location_facility: Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

location_facility: Clinical Research Center Early-Phase Research Facility

location_facility: Johann Wolfgang Goethe University Hospital

location_facility: Vilnius University Hospital Santariskiu Klinikos

location_facility: Sart Tilman Hospital Department of Gastroenterology and Hepatology

location_facility: Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

location_facility: Integrated University Hospital Santa Maria della Misericordia of Udine

location_facility: Non-Public Healthcare Facility Allmedica Clinical Trials

location_facility: Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

location_facility: University Hospital Marques de Valdecilla (HUMV)

location_facility: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

location_facility: Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi

location_facility: Practice for Gastroenterology and Internal Medicine

location_facility: SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego

location_facility: Humanitas Research Hospital - Humanitas Mirasole S.p.A

location_facility: Bucharest University Emergency Hospital, Department of Internal Medicine II

location_facility: Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University

location_facility: Vilnius University Hospital Santariskes Clinics

location_facility: Ankara University Medical Faculty Cebeci Hospital

location_facility: University Hospital Puerta de Hierro Majadajonda

location_facility: The Seventh Medical Center of PLA General Hospital

location_facility: Bezmialem Foundation University Medical Faculty

location_facility: Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra

location_facility: Soukroma Gastroenterologicka ambulance a endoskopie

location_facility: Jan Mikulicz Radecki University Hospital

location_facility: Ivano-Frankivsk Regional Clinical Hospital

location_facility: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

location_facility: Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V.

location_facility: Research Associates of South Florida LLC

location_facility: DiGiovanna Institute for Medical Education And Research

location_facility: Bat Yamon Medical Center, Clalit Medical Services

location_facility: Institut klinicke a experimentalni mediciny

location_facility: University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD

location_facility: Moscow Clinical Scientific and Practical Center

location_facility: Universitaetsklinikum Charite - Ruppiner Kliniken GmbH

location_facility: A.N. Ryzhikh State Research Center for Coloproctology

location_facility: Queen Fabiola Children's University Hospital

location_facility: Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED

location_facility: University Hospital Centre Zagreb, Clinic of Internal Diseases

location_facility: Universidad Nacional De Rosario - Hospital Provincial Del Centenario

location_facility: Instituto Tecnológico y de Estudios Superiores de Monterrey

location_facility: N.N. Burdenko Penza Regional Clinical Hospital

location_facility: Children's Center for Digestive Healthcare

location_facility: Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: General Hospital Djordje Jovanovic Zrenjanin

location_facility: Advance Clinical Research - Dayton Internal Medicine

location_facility: JSC Evex Medical Corporation - Telavi Referral Hospital

location_facility: Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes

location_facility: Centre Hospitalier Intercommunal de Creteil

location_facility: University of Massachusetts Memorial Medical Center

location_facility: Primorsky Regional Clinical Hospital No.1

location_facility: TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC

location_facility: Helsicore - Israeli Georgian Medical Research Clinic

location_facility: Interdisciplinary Crohn Colitis Center Rhein Main

location_facility: Semmelweis Egyetem - Altalanos Orvostudomanyi Kar

location_facility: Santa Familia Centrum Badan, Profilaktyki i Leczenia

location_facility: Istanbul Medeniyet Uni Goztepe Training&Res Hosp

location_facility: Rush University Medical Center - University Cardiovascular Surgeons

location_facility: ACIBADEM City Clinic Medical Center Bregalnitsa

location_facility: Csongrad County Dr. Bugyi Istvan Hospital

location_facility: JSC Evex Medical Corporation - Batumi Referral Hospital

location_facility: Maternal Pediatric and Adolescent Healthcare Centre

location_facility: Centro de Investigacion Clinica Acelerada (CICA) S.C.

location_facility: Univerisity Polyclinic Foundation Agostino Gemelli

location_facility: The Center for Gastrointestinal Disorders

location_facility: H-T. Medical Center Sp. z o.o. LLC Limited Partnership

location_facility: Ok Clinic Medical Center within International Institute of Clinical Trials, LLC

location_facility: Republican Clinical Hospital, Department of Colorectal Surgery

location_facility: Washington University School of Medicine

location_facility: Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat

location_facility: Gastroenterology Associates Of Central Georgia LLC

location_facility: Maggiore Polyclinic Hospital, IRCCS Ca' Granda

location_facility: Clinical Hospital Center - Dr. Dragisa Misovic-Dedinje

location_facility: Azienda Ospedaliera San Camillo Forlanini

location_facility: The Second Affiliated Hospital Of Zhengzhou University

location_facility: Connecticut Clinical Research Foundation

location_facility: Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases

location_facility: Atlanta Gastroenterology Associates, LLC

location_facility: GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe

location_facility: P. Stradins Clinical University Hospital

location_facility: Henry Ford Medical Center - New Center One

location_facility: Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine

location_facility: Harry Perkins Medical Research Institute, Fiona Stanley Hospital

location_facility: University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia

location_facility: Riga East Clinical University Hospital clinic Gailezers

location_facility: "Sfanta Treime" Clinical Municipal Hospital

location_facility: Instituto Medico de la Fundacion Estudios Clinicos

location_facility: Western Michigan University Homer Stryker M.D. School of Medicine

location_facility: John Hunter Hospital and Hunter Medical Research Institute

location_facility: Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University

location_facility: UC Davis Health - Gastroenterology and Hepatology Clinical Trials Unit

location_facility: Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE

location_facility: General Hospital "Prim.dr. Abdulah Nakas"

location_facility: Odesa Regional Clinical Hospital Regional Gastroenterology Center Surgery Department

location_facility: Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia

location_facility: CHU Nantes University Hospital - Hotel Dieu Hospital

location_facility: Clinical Hospital Center Zvezdara Clinic of Internal Diseases

location_facility: Cancer Care Associates of OK-N PorterAvenue

location_facility: University Clinical Hospital of Valencia

location_facility: University Clinical Centre of the Republic of Srpska

location_facility: Multidisciplinary Clinic of the St. Nicholas, LLC

location_facility: University Hospital Southampton NHS Foundation Trust - Southampton General Hospital

location_facility: VA Northern California Health Care System

location_facility: University College London Hospitals NHS Foundation Trust - University College Hospital

location_facility: Goztepe Prof. Dr. Suleyman Yalcin City Hospital

location_facility: West Edmonton Gastroenterology Consultants

location_facility: Toronto Digestive Disease Associates Inc

location_facility: CHU de Dijon Bourgogne - Hopital Francois Mitterand

location_facility: Penn State Milton S Hershey Medical Center

location_facility: Hospital of Lithuanian University of Health Sciences Kaunas Clinics

location_facility: V.T. Zaitsev Institute of General and Emergency Surgery

location_facility: Southern California Research Institute Medical Group, Inc.

location_facility: Ural State Medical Academy - Medical Association Novaya Bolnitsa

location_facility: University of Florida Health Endocrinology - Medical Specialties - Medical Plaza

location_facility: JSC Infectious Disease, AIDS and Clinical Immunology Research Center

location_facility: Univerzitna nemocnica Bratislava, Nemocnica Ruzinov

location_facility: Allergy, Asthma and Immunology Center, PC

location_facility: Craiova County Emergency Clinical Hospital

location_facility: Universitair Ziekenhuis Leuven, Campus Gasthuisberg

location_facility: Center of Diagnosis and Treatment Provita

location_facility: Multiprofile Hospital for Active Treatment Medline

location_facility: Seoul National University Bundang Hospital

location_facility: Irkutsk State Medical Academy of Postgraduate Education

location_facility: Scientific Research Institute of Physiology and Basic Medicine

location_facility: Bulent Ecevit Universitesi Uygulama ve Arastirma Hastanesi

location_facility: BIK-KYIV Ukrainian German Gastroenterology Center

location_facility: Diagnostic-Consultative Center Sveta Anna

location_facility: University Hospital Germans Trias i Pujol

location_facility: Vitebsk Regional Clinical Specialized Center

location_facility: Samara Station Railway Clinical Hospital under OAO Russian Railways

location_facility: Kindred Medical Institute for Clinical Trials, LLC

location_facility: Carolinas HealthCare System Digestive Health

location_facility: Paramount Medical Research & Consulting, LLC

location_facility: Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

location_facility: Hospital Universitario de Gran Canaria Dr. Negrin

location_facility: Vancouver Hospital Gastrointestinal Research Unit The Gordon and Leslie Diamond Centre

location_facility: The First Affiliated Hospital of Nanchang University

location_facility: Gastroenterological Special Practice at Wittenbergplatz

location_facility: Zhangzhou Municipal Hospital of Fujian Province

location_facility: University of California at San Francisco

location_facility: University Hospital of Girona Dr. Josep Trueta

location_facility: S.V. Beliaev Kemerovo Regional Clinical Hospital

location_facility: Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz

location_facility: University of Pennsylvania Cancer Center

location_facility: Hospital Privado Centro Medico de Cordoba

location_facility: Medical Scientific Manufacturing Association Dvizheniye Clinic

location_facility: Diagnostic and Consulting Center Alexandrovska

location_facility: Salve Limited Liability Company Limited Partnership, Outpatient Clinic

location_facility: Medical Center of Far-Eastern Federal University

location_facility: Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi

location_facility: Chang Gung Medical Foundation, Kaohsiung Memorial Hospital

location_facility: Advanced Research for Health Improvement

location_facility: SPb SBIH City Hospital of Saint Martyr Elizaveta

location_facility: Helsinki University Central Hospital (HUCH)

location_facility: University of Calgary Health - The Gastrointestinal Research Group (GIRG)

location_facility: Public City Clinical Hospital of Emergency Medical Care

location_facility: Kornel Gibinski Independent Public Central Clinical Hospital in Katowice

location_facility: Budget Institution of the Khanty-Mansiysk Autonomous Okrug - Ugra Surgut Regional Clinical Hospital

location_facility: Saint-Etienne University Hospital Center

location_facility: Biopharma Informatic Inc. Research Center

location_facility: Clinical Center of Vojvodina, Clinic of Gastroenterology and Hepatology

location_facility: Medical Center Medical Clinic Blagomed LLC

location_facility: Brigham and Women's Hospital - Crohn's and Colitis Center

location_facility: Ohio State University Wexner Medical Center

location_facility: London Health Sciences Centre, University Hospital

location_facility: Poltava M.V. Sklifosovskyi Regional Clinical Hospital under Poltava Regional Council

location_facility: Vrije Universiteit Medisch Centrum (VUMC)

location_facility: Sotiria Chest Diseases Hospital of Athens

location_facility: St. John Paul 2nd Municipal Hospital in Elblag

location_facility: Korea University Medical Center - Korea University Ansan Hospital

location_facility: Ivano-Frankivsk Central City Clinical Hospital

location_facility: Clinical and Diagnostic Center with an outpatient department under the Presidential Executive Office

location_facility: Targu Mures County Emergency Clinical Hospital

location_facility: "Sf. Arhanghel Mihail" Municipal Clinical Hospital

location_facility: Federal Siberian Research and Clinical Center

location_facility: Texas Digestive Disease Consultants - Southlake

location_facility: Gastroenterology Associates of Orangeburg

location_facility: Dnipropetrovsk II Mechnykov Regional Clinical Hospital Surgery Department 2

location_facility: I.I. Mechnikov North-Western State Medical University

location_facility: Hospital Christus Muquerza del Parque S.A. de C.V.

location_facility: Euromed Multi-Specialty Center for Contemporary Medicine LLC

location_facility: Palo Alto Center-Palo Alto Medical Foundation Research Institute

location_facility: University Hospital of the Canary Islands (HUC) La Laguna

location_facility: Ternopil City Public Emergency Medical Care Hospital

location_facility: University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD

location_facility: University Polyclinic Hospital G. Martino

location_facility: Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases

location_facility: General Hospital of Thessaloniki Hippokration

location_facility: LTD Academician N.Kipshidze Central University Clinic

location_facility: Provincial Specialist Hospital in Olsztyn

location_facility: G.G. Kuvatov Republican Clinical Hospital

location_facility: Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery

location_facility: Centro Regiomontano de Estudios Clinicos Roma SC.

location_facility: Vinnytsia M.I. Pyrohov Regional Clinical Hospital

location_facility: Endoterapia PFG LLC, Endotherapy PFG Outpatient Clinic Branch No 1

location_facility: Penn State University Milton S Hershey Medical Center

location_facility: World of the Health Inc. General Hospital Rimavska Sobota

location_facility: Military Medical Academy, Clinic of Gastroenterology and Hepatology

location_facility: Asheville Gastroenterology Associates, P.A.

location_facility: Cotton ONeil Clinical Research Center Digestive Health

location_facility: Cleveland Clinic - Taussig Cancer Institute

location_facility: State Unitary Enterprise Passengeravtotrans

title: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

summary: This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.